Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 5.42
ANAC's Cash to Debt is ranked higher than
66% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. ANAC: 5.42 )
ANAC' s 10-Year Cash to Debt Range
Min: 0.67   Max: No Debt
Current: 5.42

Equity to Asset 0.71
ANAC's Equity to Asset is ranked higher than
75% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ANAC: 0.71 )
ANAC' s 10-Year Equity to Asset Range
Min: -6.53   Max: 0.71
Current: 0.71

-6.53
0.71
Interest Coverage 22.84
ANAC's Interest Coverage is ranked higher than
56% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ANAC: 22.84 )
ANAC' s 10-Year Interest Coverage Range
Min: 22.84   Max: 22.84
Current: 22.84

F-Score: 7
Z-Score: 9.65
M-Score: 4.50
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) 537.02
ANAC's Operating margin (%) is ranked higher than
100% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. ANAC: 537.02 )
ANAC' s 10-Year Operating margin (%) Range
Min: -15647.66   Max: 537.02
Current: 537.02

-15647.66
537.02
Net-margin (%) 492.02
ANAC's Net-margin (%) is ranked higher than
99% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. ANAC: 492.02 )
ANAC' s 10-Year Net-margin (%) Range
Min: -15368.22   Max: 492.02
Current: 492.02

-15368.22
492.02
ROE (%) 69.80
ANAC's ROE (%) is ranked higher than
99% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -21.87 vs. ANAC: 69.80 )
ANAC' s 10-Year ROE (%) Range
Min: -1165.81   Max: 69.8
Current: 69.8

-1165.81
69.8
ROA (%) 49.23
ANAC's ROA (%) is ranked higher than
99% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. ANAC: 49.23 )
ANAC' s 10-Year ROA (%) Range
Min: -300.58   Max: 49.23
Current: 49.23

-300.58
49.23
ROC (Joel Greenblatt) (%) 6345.47
ANAC's ROC (Joel Greenblatt) (%) is ranked higher than
100% of the 872 Companies
in the Global Biotechnology industry.

( Industry Median: -196.35 vs. ANAC: 6345.47 )
ANAC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4368.24   Max: 6345.47
Current: 6345.47

-4368.24
6345.47
Revenue Growth (%) -34.10
ANAC's Revenue Growth (%) is ranked higher than
61% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -1.30 vs. ANAC: -34.10 )
ANAC' s 10-Year Revenue Growth (%) Range
Min: -70.5   Max: 467.9
Current: -34.1

-70.5
467.9
» ANAC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2012

ANAC Guru Trades in Q4 2012

Jean-Marie Eveillard 92,390 sh (New)
» More
Q1 2013

ANAC Guru Trades in Q1 2013

Jean-Marie Eveillard Sold Out
» More
Q3 2013

ANAC Guru Trades in Q3 2013

Steven Cohen 248,478 sh (New)
» More
Q4 2013

ANAC Guru Trades in Q4 2013

Jim Simons 105,800 sh (New)
Steven Cohen 604,900 sh (+143.44%)
» More
» Details

Insider Trades

Latest Guru Trades with ANAC

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2013-03-31 Sold Out 0.0017%$3.15 - $6.52 $ 15.51259%0
Jean-Marie Eveillard 2012-12-31 New Buy$4.6 - $6.81 $ 15.51180%92390
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Anacor Pharmaceuticals, Inc.

Weekly CFO Buys Highlight
According to GuruFocus Insider Data , these are the largest CFO buys during the past week. The overall trend of CFOs is illustrated in the chart below: Read more...
Senior Vice President and CFO of Anacor Pharmaceuticals Inc. Geoffrey Parker Bought 43,046 Shares
Anacor Pharmaceuticals Inc. was incorporated in the state of Delaware on Dec. 14, 2000. Anacor Pharmaceuticals Inc. has a market cap of $209.4 million; its shares were traded at around $5.11 with and P/S ratio of 17.20. Read more...
This Week's Top Insider Buys
Tuesday was certainly a busy day for insider buying, as we saw three companies reporting insider buys coming from their corporate executives costing them over $100,000. The following companies reported significant insider buys coming from their CEOs and/or CFOs with transaction amounts over $100,000.[b] Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 9.30
ANAC's P/E(ttm) is ranked higher than
92% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 28.60 vs. ANAC: 9.30 )
ANAC' s 10-Year P/E(ttm) Range
Min: 9   Max: 12.61
Current: 9.3

9
12.61
P/B 5.30
ANAC's P/B is ranked higher than
54% of the 791 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. ANAC: 5.30 )
ANAC' s 10-Year P/B Range
Min: 2.44   Max: 177.5
Current: 5.3

2.44
177.5
P/S 36.40
ANAC's P/S is ranked lower than
74% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 10.27 vs. ANAC: 36.40 )
ANAC' s 10-Year P/S Range
Min: 0.3   Max: 50.5
Current: 36.4

0.3
50.5
PFCF 8.50
ANAC's PFCF is ranked higher than
93% of the 203 Companies
in the Global Biotechnology industry.

( Industry Median: 30.00 vs. ANAC: 8.50 )
ANAC' s 10-Year PFCF Range
Min: 0.67   Max: 11.72
Current: 8.5

0.67
11.72
EV-to-EBIT 5.80
ANAC's EV-to-EBIT is ranked higher than
87% of the 468 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. ANAC: 5.80 )
ANAC' s 10-Year EV-to-EBIT Range
Min: 6.7   Max: 9.1
Current: 5.8

6.7
9.1

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.30
ANAC's Price/Net Cash is ranked higher than
70% of the 477 Companies
in the Global Biotechnology industry.

( Industry Median: 9.30 vs. ANAC: 6.30 )
ANAC' s 10-Year Price/Net Cash Range
Min: 2.95   Max: 20
Current: 6.3

2.95
20
Price/Net Current Asset Value 6.20
ANAC's Price/Net Current Asset Value is ranked higher than
69% of the 525 Companies
in the Global Biotechnology industry.

( Industry Median: 9.60 vs. ANAC: 6.20 )
ANAC' s 10-Year Price/Net Current Asset Value Range
Min: 2.9   Max: 18.24
Current: 6.2

2.9
18.24
Price/Tangible Book 5.20
ANAC's Price/Tangible Book is ranked higher than
62% of the 736 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. ANAC: 5.20 )
ANAC' s 10-Year Price/Tangible Book Range
Min: 2.67   Max: 37.14
Current: 5.2

2.67
37.14
Price/DCF (Projected) 36.10
ANAC's Price/DCF (Projected) is ranked lower than
80% of the 210 Companies
in the Global Biotechnology industry.

( Industry Median: 2.80 vs. ANAC: 36.10 )
ANAC' s 10-Year Price/DCF (Projected) Range
Min: 39.02   Max: 39.02
Current: 36.1

Price/Median PS Value 3.70
ANAC's Price/Median PS Value is ranked lower than
73% of the 725 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. ANAC: 3.70 )
ANAC' s 10-Year Price/Median PS Value Range
Min: 0.03   Max: 4.03
Current: 3.7

0.03
4.03
Price/Graham Number 1.30
ANAC's Price/Graham Number is ranked higher than
86% of the 243 Companies
in the Global Biotechnology industry.

( Industry Median: 3.00 vs. ANAC: 1.30 )
ANAC' s 10-Year Price/Graham Number Range
Min: 1.42   Max: 1.42
Current: 1.3

Earnings Yield (Greenblatt) 17.10
ANAC's Earnings Yield (Greenblatt) is ranked higher than
83% of the 378 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. ANAC: 17.10 )
ANAC' s 10-Year Earnings Yield (Greenblatt) Range
Min: 11   Max: 17.7
Current: 17.1

11
17.7
Forward Rate of Return (Yacktman) -29.28
ANAC's Forward Rate of Return (Yacktman) is ranked higher than
66% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. ANAC: -29.28 )
ANAC' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -34.9   Max: -27
Current: -29.28

-34.9
-27

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:44A.Germany
Anacor Pharmaceuticals, Inc. was incorporated in Delaware in December 2000 and began business operations in March 2002. It was formerly known as AnaMax, Inc. and changed its name to Anacor Pharmaceuticals, Inc. in 2002. The Company engages in the discovery, development and commercialization of novel small molecule therapeutics derived from its novel boron chemistry platform. Its lead candidates aim to treat onychomycosis, psoriasis, and hospital-acquired bacterial infections. Its lead product candidates include tavaborole, an antifungal product candidate in Phase III clinical development for the treatment of onychomycosis; and AN2728, an anti-inflammatory product candidate that completed Phase II clinical trials for the treatment of atopic dermatitis and psoriasis. It also engages in developing GSK2251052, or GSK '052, a systemic antibiotic product candidate in Phase II clinical development for the treatment of infections caused by Gram-negative bacteria; AN8194 for the treatment of an animal health indication; and AN5568, a Phase I human clinical trial product targeting human African trypanosomiasis. The Company's clinical pipeline also includes AN2718, a topical antifungal product candidate, which is in Phase I clinical trials for the treatment of onychomycosis and fungal infections of the skin; and AN2898, a topical anti-inflammatory product candidate in the Phase IIa clinical trials for the treatment of atopic dermatitis and psoriasis. It has research, development, and collaboration agreements with GlaxoSmithKline LLC; Eli Lilly and Company; Medicis Pharmaceutical Corporation; and Medicines for Malaria Ventures.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide